Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 12:36 AM
Ignite Modification Date: 2025-12-25 @ 10:44 PM
NCT ID: NCT02278367
Description: AEs defined as occurring or worsening after injection, within 48 hours, at an imaging visit. AEs occurring after administration, but outside that window were not reported, unless considered attributable to study drug. Note: AE results differ from results reported above because this section reports ALL adverse events, regardless of investigator's designation of relatedness.
Frequency Threshold: 0.5
Time Frame: AEs were collected at scan visit and for 48 hours after flortaucipir administration.
Study: NCT02278367
Study Brief: Clinical Evaluation of Flortaucipir F 18
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Cognitively Impaired Cognitively impaired subjects receiving a flortaucipir PET scan 0 None 0 69 6 69 View
Cognitively Normal Cognitively normal subjects receiving a flortaucipir PET scan 0 None 0 110 16 110 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
nasopharyngitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (17.1) View
procedural headache SYSTEMATIC_ASSESSMENT Injury, poisoning and procedural complications MedDRA (17.1) View
insomnia SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA (17.1) View
loss of bladder sensation SYSTEMATIC_ASSESSMENT Renal and urinary disorders MedDRA (17.1) View
hyperhidrosis SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (17.1) View
headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.1) View
dysgeusia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.1) View
dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.1) View
paraesthesia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.1) View
injection site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
asthenia SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
feeling abnormal SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
gait abnormal SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
injection site coldness SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.1) View
blood pressure increased SYSTEMATIC_ASSESSMENT Investigations MedDRA (17.1) View
dry mouth SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.1) View
nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.1) View
palpitations SYSTEMATIC_ASSESSMENT Cardiac disorders MedDRA (17.1) View